Table 2.
Primary outcome measure PTSD severity.
| PTSD Experimental Group |
PTSD Sham-Control Group |
|||||
|---|---|---|---|---|---|---|
| Pre-NFB | Post-NFB | 3- Month Follow-up | Pre-NFB | Post-NFB | 3-Month Follow-up | |
| CAPS-Total | 36.86 (10.36) | 24.39 (15.61)* | 23.58 (14.09) * | 39.94 (7.83) | 32.78 (12.27) | 31.78 (12.86) |
| % CAPS Reduction | – | 33.8% (Clinically meaningful reduction) | 36.0% (Clinically meaningful reduction) | – | 17.9% | 20.4% |
| Result Summary | – | Reduced compared to Pre-NFB (p < .008, dz = 0.71) | Reduced compared to Pre-NFB (p < .005, dz = 0.77) | – | ns (dz = 0.56) | ns (dz = 0.63). |
PTSD = Posttraumatic Stress Disorder, CAPS = Clinician Administered PTSD Scale (Normalized to CAPS-5), NFB = Neurofeedback. *Indicates significantly reduced clinical measures within a PTSD group as compared to pre-NFB baseline.